1. Alfred Jaretzki III, MD. Issue 3 (5th August 2014) Authors: Wolfe, Gil I.; Rowland, Lewis P. Journal: Muscle & nerve Issue: Volume 50:Issue 3(2014:Sep.) Page Start: 311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Asymptomatic/pauci‐symptomatic creatine kinase elevations (hyperckemia). Issue 6 (29th April 2013) Authors: Silvestri, Nicholas J.; Wolfe, Gil I. Journal: Muscle & nerve Issue: Volume 47:Issue 6(2013:Jun.) Page Start: 805 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Author response: International consensus guidance for management of myasthenia gravis. (31st January 2017) Authors: Sanders, Donald B.; Wolfe, Gil I.; Narayanaswami, Pushpa Journal: Neurology Issue: Volume 88:Number 5(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Author Response: International consensus guidance for management of myasthenia gravis: Executive summary. (31st January 2017) Authors: Sanders, Donald B.; Wolfe, Gil I.; Narayanaswami, Pushpa Journal: Neurology Issue: Volume 88:Number 5(2017) Page Start: 505 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comment: Salbutamol—A means to an endplate. (16th February 2016) Authors: Wolfe, Gil I.; Silvestri, Nicholas J. Journal: Neurology Issue: Volume 86:Number 7(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Developing treatment guidelines for myasthenia gravis. Issue 1 (30th January 2018) Authors: Sanders, Donald B.; Wolfe, Gil I.; Narayanaswami, Pushpa Journal: Annals of the New York Academy of Sciences Issue: Volume 1412:Issue 1(2018) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3, 4‐diaminopyridine. Issue 2 (21st December 2015) Authors: Burns, Ted M.; Smith, Gordon A.; Allen, Jeffrey A.; Amato, Anthony A.; Arnold, W. David; Barohn, Richard; Benatar, Michael; Bird, Shawn J.; Bromberg, Mark; Chahin, Nizar; Ciafaloni, Emma; Cohen, Jeffrey A.; Corse, Andrea; Crum, Brian A.; David, William S.; Dimberg, Elliot; Sousa, Eduardo A. De; D... Journal: Muscle & nerve Issue: Volume 53:Issue 2(2016) Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial. Issue 3 (27th January 2016) Authors: Benatar, Michael; Mcdermott, Michael P.; Sanders, Donald B.; Wolfe, Gil I.; Barohn, Richard J.; Nowak, Richard J.; Hehir, Michael; Juel, Vern; Katzberg, Hans; Tawil, Rabi Journal: Muscle & nerve Issue: Volume 53:Issue 3(2016) Page Start: 363 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. International consensus guidance for management of myasthenia gravis: Executive summary. (26th July 2016) Authors: Sanders, Donald B.; Wolfe, Gil I.; Benatar, Michael; Evoli, Amelia; Gilhus, Nils E.; Illa, Isabel; Kuntz, Nancy; Massey, Janice M.; Melms, Arthur; Murai, Hiroyuki; Nicolle, Michael; Palace, Jacqueline; Richman, David P.; Verschuuren, Jan; Narayanaswami, Pushpa Journal: Neurology Issue: Volume 87:Number 4(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Is the treatment of myasthenia gravis improving?: Why not ask our patients?. (22nd September 2020) Authors: Piehl, Fredrik; Wolfe, Gil I. Journal: Neurology Issue: Volume 95:Number 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗